An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies-Reference-Cited by-同舟云学术

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Published:2021-12-27 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

VanBlargan Laura¹^ORCID,Errico John²^ORCID,Halfmann Peter³,Zost Seth⁴^ORCID,Crowe James⁵^ORCID,Purcell Lisa⁶,Kawaoka Yoshihiro⁷^ORCID,Corti Davide⁸^ORCID,Fremont Daved⁹^ORCID,Diamond Michael¹⁰^ORCID

Affiliation:

1. Department of Medicine, Washington University School of Medicine

2. Department of Pathology & Immunology, Washington University School of Medicine

3. Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison

4. Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Department of Pediatrics Vanderbilt University Medical Center

5. Vanderbilt Vaccine Center, Vanderbilt University Medical Center; Department of Pediatrics Vanderbilt University Medical Center; Department of Pathology, and Microbiology and Immunology, Vanderbilt University Medical Center

6. Vir Biotechnology

7. Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo

8. Humabs BioMed SA, a subsidiary of Vir Biotechnology

9. Department of Pathology & Immunology, Washington University School of Medicine; Department of Molecular Microbiology, Washington University School of Medicine; Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine

10. Department of Medicine and Department of Pathology & Immunology and Department of Molecular Microbiology, Washington University School of Medicine; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine

Abstract

Abstract The emergence of the highly-transmissible B.1.1.529 Omicron variant of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. Here, we tested a panel of anti-receptor binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 [Sotrovimab]), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Lilly (LY-CoV555 and LY-CoV016), and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use may lose efficacy against the B.1.1.529 Omicron variant.

Publisher

Research Square Platform LLC

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada;2023-09-03

2. A study on the effect of natural products against the transmission of B.1.1.529 Omicron;Virology Journal;2023-08-25

3. A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines;Gut Microbes;2023-07-11

4. Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro;Frontiers in Immunology;2023-03-08

5. Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants;Frontiers in Immunology;2023-02-21